Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
ScD Colin R Dormuth, MPH Jason D Kim, MD Anat Fisher, PhD Jolanta Piszczek, I Fan Kuo
JAMA Network Open, doi:10.1001/jamanetworkopen.2023.36678
IMPORTANCE Postmarket analysis of individuals who receive nirmatrelvir and ritonavir (Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in published clinical trials. OBJECTIVE To examine the association of nirmatrelvir and ritonavir with prevention of death or admission to hospital in individuals with different risks of complications from COVID-19 infection. DESIGN, SETTING, AND PARTICIPANTS This is a cohort study of adult patients in British Columbia, Canada, between February 1, 2022, and February 3, 2023. Patients were eligible if they belonged to 1 of 4 higher-risk groups of individuals who received priority for COVID-19 vaccination. Two groups included clinically extremely vulnerable (CEV) people who were severely (CEV1) or moderately immunocompromised (CEV2). CEV3 individuals were not immunocompromised but had medical conditions associated with a high risk for complications from COVID-19. A fourth expanded eligibility (EXEL) group was added to allow wider access to nirmatrelvir and ritonavir for certain other higherrisk individuals who were not in a CEV group, such as those older than 70 years who were unvaccinated. EXPOSURES Patients with COVID-19 who received nirmatrelvir and ritonavir were matched to patients in the same vulnerability group; who were of the same sex, age, and propensity score for nirmatrelvir and ritonavir treatment; and who were also infected within 1 month of the individual treated with nirmatrelvir and ritonavir.
MAIN OUTCOMES AND MEASURES The primary outcome was death from any cause or emergency hospitalization with COVID-19 within 28 days. RESULTS There were 6866 individuals included in the study, of whom 3888 (56.6%) were female and whose median (IQR) age was 70 (57-80) years. Compared with unexposed controls, treatment with nirmatrelvir and ritonavir was associated with statistically significant relative reductions in the primary outcome in the CEV1 group (560 patients; risk difference [RD], -2.5%, 95% CI, -4.8% to -0.2%) and the CEV2 group (2628 patients; RD, -1.7%; 95% CI, -2.9% to -0.5%). In the CEV3 group, the RD was -1.3%, but the findings were not statistically significant (2100 patients; 95% CI, -2.8% to 0.1%). In the EXEL group, treatment was associated with higher risk of the outcome (RD, 1.0%), but the findings were not statistically significant (1578 patients; 95% CI, -0.9% to 2.9%).
CONCLUSIONS AND RELEVANCE In this cohort study of 6866 individuals in British Columbia, nirmatrelvir and ritonavir treatment was associated with reduced risk of COVID-19 hospitalization or death in CEV individuals, with the greatest benefit observed in severely immunocompromised (continued) Key Points Question What is the association of nirmatrelvir and ritonavir exposure with the risk of death or COVID-19-related hospitalization when accounting for patient vulnerability to complications from COVID-19 infection? Findings In this cohort study of 6866 individuals with COVID-19,..
ARTICLE INFORMATION
References
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat,
doi:10.1002/pst.433Bc Covid, Committee, Clinical practice guide for the use of therapeutics in mild-moderate COVID-19
Clinicaltrials, Gov, Evaluation of protease inhibition for covid-19 in standard-risk patients (EPIC-SR)
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Kabore, Laffont, Diop, Tardif, Turgeon et al., Real-world effectiveness of nirmatrelvir/ ritonavir on coronavirus disease 2019 (COVID-19)-associated hospitalization prevention: a population-based cohort study in the province of quebec, canada, Clin Infect Dis,
doi:10.1093/cid/ciad287Latouche, Allignol, Beyersmann, Labopin, Fine, A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions, J Clin Epidemiol,
doi:10.1016/j.jclinepi.2012.09.017Pfizer, Pfizer reports additional data on Paxlovid supporting upcoming new drug application submission to, U.S. FDA
Schneeweiss, Rassen, Glynn, Avorn, Mogun et al., High-dimensional propensity score adjustment in studies of treatment effects using health care claims data, Epidemiology,
doi:10.1097/EDE.0b013e3181a663ccSchwartz, Wang, Tadrous, Population-based evaluation of the effectiveness of nirmatrelvirritonavir for reducing hospital admissions and mortality from COVID-19, CMAJ,
doi:10.1503/cmaj.221608{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T16:38:35Z', 'timestamp': 1711643915051},
'reference-count': 14,
'publisher': 'American Medical Association (AMA)',
'issue': '10',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:sec id="ab-zoi231060-4"><jats:title>Importance</jats:title><jats:p>Postmarket analysis '
'of individuals who receive nirmatrelvir and ritonavir (Paxlovid [Pfizer]) is essential '
'because they differ substantially from individuals included in published clinical '
'trials.</jats:p></jats:sec><jats:sec '
'id="ab-zoi231060-5"><jats:title>Objective</jats:title><jats:p>To examine the association of '
'nirmatrelvir and ritonavir with prevention of death or admission to hospital in individuals '
'with different risks of complications from COVID-19 infection.</jats:p></jats:sec><jats:sec '
'id="ab-zoi231060-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This is '
'a cohort study of adult patients in British Columbia, Canada, between February 1, 2022, and '
'February 3, 2023. Patients were eligible if they belonged to 1 of 4 higher-risk groups of '
'individuals who received priority for COVID-19 vaccination. Two groups included clinically '
'extremely vulnerable (CEV) people who were severely (CEV1) or moderately immunocompromised '
'(CEV2). CEV3 individuals were not immunocompromised but had medical conditions associated '
'with a high risk for complications from COVID-19. A fourth expanded eligibility (EXEL) group '
'was added to allow wider access to nirmatrelvir and ritonavir for certain other higher-risk '
'individuals who were not in a CEV group, such as those older than 70 years who were '
'unvaccinated.</jats:p></jats:sec><jats:sec '
'id="ab-zoi231060-7"><jats:title>Exposures</jats:title><jats:p>Patients with COVID-19 who '
'received nirmatrelvir and ritonavir were matched to patients in the same vulnerability group; '
'who were of the same sex, age, and propensity score for nirmatrelvir and ritonavir treatment; '
'and who were also infected within 1 month of the individual treated with nirmatrelvir and '
'ritonavir.</jats:p></jats:sec><jats:sec id="ab-zoi231060-8"><jats:title>Main Outcomes and '
'Measures</jats:title><jats:p>The primary outcome was death from any cause or emergency '
'hospitalization with COVID-19 within 28 days.</jats:p></jats:sec><jats:sec '
'id="ab-zoi231060-9"><jats:title>Results</jats:title><jats:p>There were 6866 individuals '
'included in the study, of whom 3888 (56.6%) were female and whose median (IQR) age was 70 '
'(57-80) years. Compared with unexposed controls, treatment with nirmatrelvir and ritonavir '
'was associated with statistically significant relative reductions in the primary outcome in '
'the CEV1 group (560 patients; risk difference [RD], −2.5%, 95% CI, −4.8% to −0.2%) and the '
'CEV2 group (2628 patients; RD, −1.7%; 95% CI, −2.9% to −0.5%). In the CEV3 group, the RD was '
'−1.3%, but the findings were not statistically significant (2100 patients; 95% CI, −2.8% to '
'0.1%). In the EXEL group, treatment was associated with higher risk of the outcome (RD, '
'1.0%), but the findings were not statistically significant (1578 patients; 95% CI, −0.9% to '
'2.9%).</jats:p></jats:sec><jats:sec id="ab-zoi231060-10"><jats:title>Conclusions and '
'Relevance</jats:title><jats:p>In this cohort study of 6866 individuals in British Columbia, '
'nirmatrelvir and ritonavir treatment was associated with reduced risk of COVID-19 '
'hospitalization or death in CEV individuals, with the greatest benefit observed in severely '
'immunocompromised individuals. No reduction in the primary outcome was observed in lower-risk '
'individuals, including those aged 70 years or older without serious '
'comorbidities.</jats:p></jats:sec>',
'DOI': '10.1001/jamanetworkopen.2023.36678',
'type': 'journal-article',
'created': {'date-parts': [[2023, 10, 2]], 'date-time': '2023-10-02T15:01:27Z', 'timestamp': 1696258887000},
'page': 'e2336678',
'source': 'Crossref',
'is-referenced-by-count': 4,
'title': 'Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With '
'Vulnerability to COVID-19 Complications',
'prefix': '10.1001',
'volume': '6',
'author': [ { 'given': 'Colin R.',
'family': 'Dormuth',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Anesthesiology, Pharmacology and Therapeutics, '
'University of British Columbia, Vancouver, British Columbia, '
'Canada'},
{ 'name': 'Therapeutics Initiative, University of British Columbia, '
'Vancouver, British Columbia, Canada'}]},
{ 'given': 'Jason D.',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Anesthesiology, Pharmacology and Therapeutics, '
'University of British Columbia, Vancouver, British Columbia, '
'Canada'},
{ 'name': 'Therapeutics Initiative, University of British Columbia, '
'Vancouver, British Columbia, Canada'}]},
{ 'given': 'Anat',
'family': 'Fisher',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Anesthesiology, Pharmacology and Therapeutics, '
'University of British Columbia, Vancouver, British Columbia, '
'Canada'},
{ 'name': 'Therapeutics Initiative, University of British Columbia, '
'Vancouver, British Columbia, Canada'}]},
{ 'given': 'Jolanta',
'family': 'Piszczek',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmaceutical Sciences, University of British '
'Columbia, Vancouver, British Columbia, Canada'},
{ 'name': 'BC COVID Therapeutics Committee, Vancouver, British Columbia, '
'Canada'}]},
{ 'given': 'I Fan',
'family': 'Kuo',
'sequence': 'additional',
'affiliation': [ { 'name': 'Pharmaceutical Laboratory and Blood Services Division, British '
'Columbia Ministry of Health, Vancouver, British Columbia, '
'Canada'}]}],
'member': '10',
'published-online': {'date-parts': [[2023, 10, 2]]},
'reference': [ { 'issue': '15',
'key': 'zoi231060r2',
'doi-asserted-by': 'publisher',
'first-page': '1397',
'DOI': '10.1056/NEJMoa2118542',
'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19.',
'volume': '386',
'author': 'Hammond',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'issue': '6',
'key': 'zoi231060r5',
'doi-asserted-by': 'publisher',
'first-page': 'E220',
'DOI': '10.1503/cmaj.221608',
'article-title': 'Population-based evaluation of the effectiveness of '
'nirmatrelvir-ritonavir for reducing hospital admissions and mortality '
'from COVID-19.',
'volume': '195',
'author': 'Schwartz',
'year': '2023',
'journal-title': 'CMAJ'},
{ 'key': 'zoi231060r6',
'doi-asserted-by': 'publisher',
'article-title': 'Real-world effectiveness of nirmatrelvir/ritonavir on coronavirus '
'disease 2019 (COVID-19)–associated hospitalization prevention: a '
'population-based cohort study in the province of quebec, canada.',
'author': 'Kabore',
'journal-title': 'Clin Infect Dis',
'DOI': '10.1093/cid/ciad287'},
{ 'issue': '15',
'key': 'zoi231060r7',
'doi-asserted-by': 'publisher',
'first-page': '1397',
'DOI': '10.1056/NEJMoa2118542',
'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19.',
'volume': '386',
'author': 'Hammond',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'issue': '4',
'key': 'zoi231060r10',
'doi-asserted-by': 'publisher',
'first-page': '512',
'DOI': '10.1097/EDE.0b013e3181a663cc',
'article-title': 'High-dimensional propensity score adjustment in studies of treatment '
'effects using health care claims data.',
'volume': '20',
'author': 'Schneeweiss',
'year': '2009',
'journal-title': 'Epidemiology'},
{ 'issue': '2',
'key': 'zoi231060r11',
'doi-asserted-by': 'publisher',
'first-page': '150',
'DOI': '10.1002/pst.v10.2',
'article-title': 'Optimal caliper widths for propensity-score matching when estimating '
'differences in means and differences in proportions in observational '
'studies.',
'volume': '10',
'author': 'Austin',
'year': '2011',
'journal-title': 'Pharm Stat'},
{ 'key': 'zoi231060r12',
'doi-asserted-by': 'publisher',
'first-page': '496',
'DOI': '10.1080/01621459.1999.10474144',
'article-title': 'A proportional hazards model for the subdistribution of a competing '
'risk.',
'volume': '94',
'author': 'Fine',
'year': '1999',
'journal-title': 'J Am Stat Assoc'},
{ 'issue': '6',
'key': 'zoi231060r13',
'doi-asserted-by': 'publisher',
'first-page': '648',
'DOI': '10.1016/j.jclinepi.2012.09.017',
'article-title': 'A competing risks analysis should report results on all cause-specific '
'hazards and cumulative incidence functions.',
'volume': '66',
'author': 'Latouche',
'year': '2013',
'journal-title': 'J Clin Epidemiol'},
{ 'issue': '3',
'key': 'zoi231060r14',
'doi-asserted-by': 'publisher',
'first-page': '557',
'DOI': '10.1093/biomet/80.3.557',
'article-title': 'Checking the Cox model with cumulative sums of martingale-based '
'residuals.',
'volume': '80',
'author': 'Lin',
'year': '1993',
'journal-title': 'Biometrika'},
{ 'key': 'zoi231060r1',
'unstructured': 'Government of Canada. Summary basis of decision—Paxlovid—Health Canada. '
'Accessed August 29, 2023. '
'https://covid-vaccine.canada.ca/info/summary-basis-decision-detailTwo.html?linkID=SBD00577'},
{ 'key': 'zoi231060r3',
'unstructured': 'ClinicalTrials.gov. Evaluation of protease inhibition for covid-19 in '
'standard-risk patients (EPIC-SR). August 18, 2021. Accessed August 29, '
'2023. https://classic.clinicaltrials.gov/ct2/show/NCT05011513'},
{ 'key': 'zoi231060r4',
'unstructured': 'Pfizer. Pfizer reports additional data on Paxlovid supporting upcoming '
'new drug application submission to U.S. FDA. June 14, 2022. Accessed '
'August 29, 2023. '
'https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting'},
{ 'key': 'zoi231060r8',
'unstructured': 'BC COVID Therapeutics Committee. Clinical practice guide for the use of '
'therapeutics in mild-moderate COVID-19. January 10, 2023. Accessed '
'August 29, 2023. '
'http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/ClinicalPracticeGuide_Therapeutics_MildModerateCOVID.pdf'},
{ 'key': 'zoi231060r9',
'unstructured': 'National Advisory Committee on Immunization (NACI). Guidance on COVID-19 '
'vaccine booster doses: initial considerations for 2023. January 20, '
'2023. Accessed August 29, 2023. '
'https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses-initial-considerations-2023.html'}],
'container-title': 'JAMA Network Open',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2809972/dormuth_2023_oi_231060_1707500836.98378.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 2, 14]],
'date-time': '2024-02-14T16:02:54Z',
'timestamp': 1707926574000},
'score': 1,
'resource': {'primary': {'URL': 'https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809972'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 10, 2]]},
'references-count': 14,
'journal-issue': {'issue': '10', 'published-print': {'date-parts': [[2023, 10, 2]]}},
'URL': 'http://dx.doi.org/10.1001/jamanetworkopen.2023.36678',
'relation': {},
'ISSN': ['2574-3805'],
'subject': ['General Medicine'],
'container-title-short': 'JAMA Netw Open',
'published': {'date-parts': [[2023, 10, 2]]}}
